BioSpace News Archive

Ionis Pharmaceuticals, Inc. announced positive topline results from a 35-week interim analysis of the Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca’s eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy.

Midatech Pharma PLC, an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that following the submission of an application to the European Medicines Agency, its development programme of MTX110 for the treatment of glioma has been granted Orphan Medicinal Product designation by the agency.

Enzolytics, Inc. announced it has identified conserved, immutable sites on the Monkeypox virus.

Athersys, Inc. announced the Company’s slate of director candidates for its 2022 Annual Meeting of Stockholders being held on Thursday, July 28, 2022, at 8:30 a.m. ET.

Zomedica Corp. announced that Greg Blair, Zomedica’s Vice President of Business Development & Strategic Planning, will participate in a panel discussion and will provide a deep dive into how Zomedica’s products and latest technologies are supporting veterinarians in the post-covid world at Animal Health, Nutrition & Technology Innovation USA scheduled in Boston, June 21-23, 2022.

Nuvalent, Inc. announced progress on its parallel lead clinical programs NVL-520, a novel ROS1-selective inhibitor, and NVL-655, a novel ALK-selective inhibitor.

SQZ Biotechnologies Company, focused on unlocking the full potential of cell therapies for multiple therapeutic areas, presented Tolerizing Antigen Carrier nonclinical results at the 2022 Federation of Clinical Immunology Sciences annual meeting.

Algernon Pharmaceuticals Inc. announces that patients from multiple sites participating in its Phase 2 proof of concept study of NP-120 (“Ifenprodil”) for idiopathic pulmonary fibrosis (“IPF”) and chronic cough, being conducted in Australia and New Zealand, have requested ongoing supply of Ifenprodil for their personal use beyond the study’s treatment period.

Duchesnay Inc, a pharmaceutical company specializing in women’s health and part of Duchesnay Pharmaceutical Group headquartered in Blainville, Quebec, is pleased to announce that it has launched its newest treatment, Vablys ® (dequalinium chloride vaginal tablets).

Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves over 600 employers and millions of members, today announced that it will release fiscal first quarter 2023 financial results on Thursday, June 30, 2022, after the market closes.